PRIMARY MYELOFIBROSIS (PMF)
Clinical trials for PRIMARY MYELOFIBROSIS (PMF) explained in plain language.
Never miss a new study
Get alerted when new PRIMARY MYELOFIBROSIS (PMF) trials appear
Sign up with your email to follow new studies for PRIMARY MYELOFIBROSIS (PMF), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug trial hopes to tame rare blood cancers
Disease control Recruiting nowThis early-phase study tests a new drug called PRT12396 in about 100 people with polycythemia vera or myelofibrosis, which are types of blood cancers. The main goals are to find a safe dose and see if the drug can help control the disease. Participants must have a specific gene m…
Matched conditions: PRIMARY MYELOFIBROSIS (PMF)
Phase: PHASE1 • Sponsor: Prelude Therapeutics • Aim: Disease control
Last updated May 17, 2026 00:51 UTC
-
New hope for myelofibrosis: experimental drug combo tested in japan
Disease control Recruiting nowThis early-stage study tests whether adding the experimental drug pelabresib to the standard treatment ruxolitinib is safe for Japanese adults with myelofibrosis, a rare bone marrow cancer. Only 6 participants will receive the combination to check for side effects and how the dru…
Matched conditions: PRIMARY MYELOFIBROSIS (PMF)
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 00:45 UTC
-
Desperate patients gain access to promising drug through managed programs
Disease control AVAILABLEThis program provides access to the drug ruxolitinib (INC424) for patients with serious or life-threatening conditions like certain blood cancers, severe COVID-19, or graft-versus-host disease when no other treatments are available. It is for people who cannot join a clinical tri…
Matched conditions: PRIMARY MYELOFIBROSIS (PMF)
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New combo pill shows promise for rare bone marrow cancer
Disease control Recruiting nowThis study tests whether adding pelabresib to the standard drug ruxolitinib works better than ruxolitinib alone for people with myelofibrosis, a rare bone marrow disorder. About 460 adults who have not taken JAK inhibitors before will receive either the combination or a placebo p…
Matched conditions: PRIMARY MYELOFIBROSIS (PMF)
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 11, 2026 20:50 UTC
-
New registry aims to unlock secrets of rare blood cancers
Knowledge-focused Recruiting nowThis study follows 5,000 adults with myeloproliferative neoplasms (MPNs) — rare blood cancers — to understand how symptoms change and how the disease progresses over years. Participants share their health records, insurance data, and regular surveys about how they feel. No new tr…
Matched conditions: PRIMARY MYELOFIBROSIS (PMF)
Sponsor: MPN Research Foundation • Aim: Knowledge-focused
Last updated May 04, 2026 16:17 UTC